NCT03096054 - A CR-UK Phase I Trial of LY3143921 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 21, 2017

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2027

Conditions

A. Colorectal CancerB. High Grade Serous Ovarian CancerC. Non Small-cell Lung Cancer (squamous Cell Variant)D. Squamous Carcinoma of the OesophagusE. Squamous Carcinoma of the Head and Neck (HPV Negative)F. Urothelial CancerG. Breast Cancer (triple Negative Type)H. Pancreatic Cancer

Interventions

DRUG

LY3143921 hydrate

LY3143921 hydrate will be administered orally on a daily schedule. Each cycle of treatment will consist of 21 days, and patients may initially receive up to 12 cycles. If the patient is benefitting, they may continue beyond 12 cycles.

Trial Locations (4)

BT9 7AB

Cancer Centre, Belfast City Hospital, Belfast

EH4 2XU

Western General Hospital, Edinburgh

G12 0YN

Beatson West of Scotland Cancer Centre, Glasgow

NE7 7DN

Northern Centre for Cancer Care, Newcastle upon Tyne